### Edgar Filing: Brzeczko Albert W - Form 4

Form 4				
December 11, 2017	OMB APPROVAL			
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				
Check this box if no longer subject to Section 16. Form 4 or Form 5 Eiled pursuant to Section 16(a) of the Securities Exchange Act of 1034	Expires:January 31 2009Estimated average burden hours per response0.5			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940	on			
(Print or Type Responses)				
Brzeczko Albert W Symbol Issuer ACURA PHARMACEUTICALS.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)       (First)       (Middle)       3. Date of Earliest Transaction	ve title 10% Owner Other (specify below) hnical Affairs - APT			
Filed(Month/Day/Year) Applicable Line)	Ioint/Group Filing(Check One Reporting Person			
	More than One Reporting			
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of	of, or Beneficially Owned			
Security (Instr. 3)(Month/Day/Year)Execution Date, if anyTransactionAcquired (A) or Disposed of (D)Securities(Instr. 3)anyCodeDisposed of (D)Beneficially(Month/Day/Year)(Instr. 8)(Instr. 3, 4 and 5)Owned	6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (I) Ownership (Instr. 4) (Instr. 4)			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: Brzeczko Albert W - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration E (Month/Day	ate	d 7. Title and Amount of Underlying Securities (Instr. 3 and 4)		f 8. I De Seo (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units <sup>(1)</sup>	<u>(2)</u>	12/11/2017		A	28,000	(3)	(3)	Common Stock	28,000	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Brzeczko Albert W C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE, IL 60067			VP Technical Affairs - APT		
Signatures					

# Sig

/s/ Albert 12/11/2017 Brzeczko

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Awarded under the Acura Pharmaceuticals Inc. 2017 Restricted Stock Unit Award Plan (the "Plan").
- (2) Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.

100% of Restricted Stock Units vest on December 11, 2018 or earlier if Reporting Person's service as an employee of Issuer is terminated by Issuer without Cause (as defined in the Plan) or due to Reporting Person's death or Disability (as defined in the Plan) or a qualifying

(3) change of control occurs. Distributions in respect of vested Restricted Stock Units will be made in three equal installments on the first business day of each of January 2020, 2021, and 2022 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.

(4) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.